Prominent Conservatives Expose the Hospital 340B Drug Scam

Prominent conservative leaders are increasingly calling attention to how large nonprofit hospitals are exploiting the federal 340B drug discount program to enrich themselves at taxpayer expense. What began as a program intended to help vulnerable patients afford medications has instead become a lucrative revenue stream for large hospital systems that purchase drugs at steep discounts and bill insurers and taxpayers full price.

Critics argue that the program now benefits hospital balance sheets far more than the patients it was designed to serve. Even more concerning, these large hospital systems often align with Democratic policymakers to defend the current structure of the program, which expands the role of government while blocking free-market reforms that could actually lower health care costs.

Conservative Leaders Call Out the Abuse

A growing number of conservative policy voices are highlighting the problem. In a recent op-ed in the The Washington Times, Steve Forbes argued that efforts to rein in the program deserve strong support because the current system has drifted far from its original purpose.

The issue has also been spotlighted by the Committee to Unleash Prosperity, where economist Steve Moore and his colleagues have repeatedly warned that the program has become a major financial windfall for hospital systems.

These critics point out that hospitals can purchase drugs through the program at deeply discounted prices and then charge insurers or government programs the full market rate. The hospital keeps the difference, turning what was meant to be a patient-support program into a revenue-generating scheme.

How the 340B Program Was Twisted

The 340B program is administered by the Health Resources and Services Administration and was originally intended to help safety-net providers stretch limited resources to serve low-income patients.

But over time the program expanded dramatically. Thousands of hospitals and contract pharmacies now participate, including large hospital systems that are financially strong and far removed from the safety-net mission the program was meant to support.

Crucially, hospitals are not required to pass the drug discounts on to patients. Instead, they can bill insurers or government programs at full price and keep the spread between the discounted acquisition cost and the reimbursement amount.

Critics say this loophole has transformed the program into one of the most significant hidden subsidy streams in the health care system.

Hospitals and the Politics of Bigger Government

Large nonprofit hospitals have become powerful political players in Washington. Many of these institutions actively lobby against reforms that would introduce more competition, transparency, and market discipline into the health care system.

At the same time, critics say they work closely with Democratic policymakers to preserve programs like 340B that channel large government-driven subsidies into hospital systems.

The result is a political alliance that expands government involvement in health care while resisting free-market reforms that could reduce costs and empower patients.

Congress Is Increasingly Paying Attention

Congress is beginning to scrutinize health care financing schemes that shift costs to federal taxpayers. Lawmakers recently took steps to address other hospital-driven financing abuses, including the so-called provider tax loophole, as part of the 2025 “One Big Beautiful Bill.”

Those reforms signaled growing bipartisan concern about how certain health care financing mechanisms are being used to draw down larger federal payments without improving care for patients.

The increasing attention to these practices suggests that the 340B program could face similar scrutiny as policymakers look more closely at how hospitals use federal subsidies.

CFE Takeaway

The growing criticism from conservative leaders highlights a simple problem: the 340B program has strayed far from its original mission. Instead of helping vulnerable patients access affordable medications, it too often allows large nonprofit hospital systems to profit from government-mandated discounts.

If policymakers are serious about reducing health care costs and protecting taxpayers, reforms should ensure that any drug discounts actually reach patients rather than enriching hospital systems.

Shining a light on programs like 340B is an important step toward restoring transparency, accountability, and free-market principles to the American health care system.